Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Astellas: Ten years young

Astellas: Ten years young Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide). ... There it is currently conducting a series of investigations in breast cancer to assess

NICE backs Xtandi but turns down Zytiga

NICE backs Xtandi but turns down Zytiga Astellas and Medivation's pre-chemotherapy prostate cancer drug receives support. UK cost-effectiveness agency NICE has given a boost to Astellas and Medivation's Xtandi, backing its use in ... handing an important advantage to Xtandi as it tries to claw

Astellas’ Xtandi cancer drug rejected by NICE

Astellas’ Xtandi cancer drug rejected by NICE The newly released draft guidance does not recommended Xtandi as a treatment for advanced prostate cancer. ... Xtandi is already NICE-approved for men with metastatic hormone-relapsed prostate cancer, who have already had treatment with

Prostate cancer treatment market to treble to £8.2bn by 2023

Prostate cancer treatment market to treble to £8.2bn by 2023 Canada – and is expected to be driven by a rapidly ageing population, the introduction of nine premium-priced therapies and the proposed label extensions for Zytiga and Xtandi the treatment of ... The analyst noted that the primary driver of growth

Pharma deals in February 2015

Pharma deals in February 2015 Challenges associated with turning this asset around e.g. complex production, sky-high price tag, looming competition from oral rivals Xtandi (Astellas) and Medivation) and Zytiga (J&J) will be daunting.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics